Table 2.

All grade adverse events occurring in more than one patient regardless of attributed causality *.

Adverse Event	Any Grade n = 12	Grade 3 or Higher n = 12	Any Grade Dose Level 1 n = 6	Grade 3 or Higher Dose Level 1 n = 6	Any Grade Dose Level 2 n = 6	Grade 3 or Higher Dose Level 2 n = 6
Any Adverse Event n (%)	12 (100%)	7 (58%)	6 (100%)	4 (67%)	6 (100%)	3 (50%)
Hyperglycaemia	7 (58%)	0	4 (67%)	0	3 (50%)	0
Constipation	7 (58%)	0	3 (50%)	0	4 (67%)	0
Fatigue	7 (58%)	1 (8%)	4 (67%)	1 (17%)	3 (50%)	0
Hypertension	6 (50%)	4 (33%)	5 (83%)	3 (50%)	1 (17%)	1 (17%)
Nausea	7 (58%)	0	3 (50%)	0	4 (67%)	0
Diarrhea	6 (50%)	0	3 (50%)	0	3 (50%)	0
Rash	6 (50%)	0	3 (50%)	0	3 (50%)	0
Vomiting	7 (58%)	0	4 (67%)	0	3 (50%)	0
Cough	4 (33%)	0	3 (50%)	0	1 (17%)	0
Mucositis	5 (42%)	0	4 (67%)	0	1 (17%)	0
Decreased appetite	4 (33%)	0	3 (50%)	0	1 (17%)	0
Dry skin	4 (33%)	0	3 (50%)	0	1 (17%)	0
Fever	4 (33%)	0	3 (50%)	0	1 (17%)	0
Headache	4 (33%)	0	1 (17%)	0	3 (50%)	0
Paresthesia	3 (25%)	0	1 (17%)	0	2 (33%)	0
Weight decreased	3 (25%)	0	3 (50%)	0	0	0
Anemia	2 (17%)	0	1 (17%)	0	1 (17%)	0
Dehydration	2 (17%)	0	2 (33%)	0	0	0
Dyspnea	2 (17%)	1 (8%)	1 (17%)	0	1 (17%)	1 (17%)
Oedema peripheral	1 (8%)	0	1 (17%)	0	0	0
Insomnia	2 (17%)	0	1 (17%)	0	1 (17%)	0
Paresthesia Oral	2 (17%)	0	0	0	2 (33%)	0
Peripheral neuropathy	2 (17%)	0	1 (17%)	0	1 (17%)	0
Blood Bilirubin increased	1 (8%)	1 (8%)	0	0	1 (17%)	1 (17%)
Gamma GT increased	1 (8%)	1 (8%)	0	0	1 (17%)	1 (17%)
Bile duct obstruction	1 (8%)	1 (8%)	0	0	1 (17%)	1 (17%)
Lymphangitis carcinomatosis	1 (8%)	1 (8%)	0	0	1 (17%)	1 (17%)

* If an event ≥grade 3 occurred in a single patient, the event is included here. Gamma GT–Gamma-Glutamyl Transferase.